Apolipoprotein E (ApoE), a novel heparin-binding protein inhibits the development of Kaposi's sarcoma-like lesions in BALB/c nu/nu mice.
Recombinant apolipoprotein E-3 (ApoE-3), expressed in Escherichia coli, was purified and used in an in vitro and an in vivo model system for acquired immunodeficiency syndrome-associated Kaposi's sarcoma (AIDS-KS). This protein blocked cell proliferation and chemotaxis of AIDS-KS cells in response to activated lymphocyte conditioned medium (AL-CM) and oncostatin M (OSM). ApoE-3 also inhibited the formation of neoangiogenic lesions induced in BALB/c nu/nu mice by AIDS-KS cells. These findings represent a novel and potentially less toxic therapeutic approach for the treatment of AIDS-KS.
Browning
P J
PJ
Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
Roberts
D D
DD
Zabrenetzky
V
V
Bryant
J
J
Kaplan
M
M
Washington
R H
RH
Panet
A
A
Gallo
R C
RC
Vogel
T
T
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000818:Animals; D053318:Apolipoprotein E3; D001057:Apolipoproteins E / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D004247:DNA / Q000096:biosynthesis; D015497:HIV-1; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D011994:Recombinant Proteins / Q000627:therapeutic use; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000473:pathology
D053318:Apolipoprotein E3; D001057:Apolipoproteins E; D011994:Recombinant Proteins; D004247:DNA